Regulatory Surveillance
Regulatory Surveillance - Related Videos
02:02
Cis-regulatory Sequences
0 Views •
2020
Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
0 Views •
2025
Overtreatment is often administered to patients with low-risk prostate cancer; super-active surveillance can help avoid such overtreatment.
01:26
Principles of Disease Surveillance
0 Views •
2025
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
01:27
Immune Surveillance by NK Cells and Phagocytes
0 Views •
2026
Immune surveillance is an integral part of the innate immune system, involving the continuous monitoring of peripheral tissues to detect and respond to pathogens, infected cells, or cancerous cells. This surveillance is conducted primarily by natural killer (NK) cells and phagocytes, which employ distinct but complementary mechanisms to identify and eliminate threats. Natural Killer Cells: The Fast Responders NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
0 Views •
Cited by 2 •
2007
FAQs
Regulatory surveillance draws on several complementary evidence streams: adverse event reports, safety databases, inspections, and epidemiological studies. Each contributes a different view of product performance in real-world use. Reports and databases can reveal unexpected patterns, inspections add findings from oversight activities, and epidemiological studies help assess event frequency or associations across populations. Together, these sources strengthen detection beyond any single dataset.
A detected safety signal does not by itself prove that a medicine caused an event. Investigators evaluate whether observed events may be drug related, using the available surveillance evidence and epidemiological findings. This distinction prevents an isolated or preliminary pattern from being treated as definitive causation, while still allowing regulators and manufacturers to investigate a possible risk before making benefit-risk decisions.
Lifecycle monitoring matters because evidence can change after a product enters broader real-world use. Continued surveillance can identify new safety information, clarify how observed events relate to treatment, and support comparison of benefits with risks. In pharmacology, this ongoing evidence helps keep therapeutic decisions aligned with current findings rather than relying only on information available earlier in a product’s life cycle.
The workflow begins with collecting information from adverse event reporting, safety databases, inspections, and epidemiological studies. Signals are then detected and assessed, including evaluation of whether observed events may be drug related. Findings are considered in a benefit-risk comparison, after which regulators or manufacturers may update product information or introduce measures that address the identified concern.
Inspections contribute an oversight perspective that complements patient event reports and population-based studies. Within regulatory surveillance, they are considered alongside evidence about a product’s safety, quality, and effectiveness rather than treated as a substitute for other sources. This combination helps regulators and manufacturers examine concerns from multiple angles when assessing whether additional action is warranted.
Surveillance findings can lead to several responses, including updates to product information, new risk-management measures, restrictions on use, or market withdrawal when necessary. The choice depends on what the accumulated evidence indicates about safety and benefits relative to risks. These actions translate pharmacovigilance findings into changes intended to protect patients and guide therapeutic decisions.